POP Biotechnologies announces phase 3 trial interim results published for COVID-19 vaccine based on POP BIO SNAP

The Associated Press reports that POP Biotechnologies—a UB spinout founded by Jonathan Lovell, SUNY Empire Innovation Professor in the Department of Biomedical Engineering—completed a study on a new recombinant COVID vaccine, EuCorVac-19. 

ECV-19 elicited a strong immune response, with a higher seroresponse rate and greater neutralizing antibody levels against both the original Wuhan strain and the Omicron variant. The vaccine uses POP BIO's SNAP™ technology and is effective against both the original virus and the Omicron variant.

The study concluded that COVID vaccines can be updated by replacing the antigen, which will accelerate the development of vaccines for COVID variants, and other illnesses. 

Read the full story here.